Chengsheng Ju1, Rachel Wing Chuen Lai2, Ka Hou Christien Li3, Joshua Kai Fung Hung2, Jenny C L Lai4, Jeffery Ho5, Yingzhi Liu6, Man Fung Tsoi7, Tong Liu8, Bernard Man Yung Cheung7, Ian Chi Kei Wong1,9, Lai Shan Tam10, Gary Tse8,11. 1. School of Pharmacy, University College London, London, UK. 2. Laboratory of Cardiovascular Electrophysiology, Li Ka Shing Institute of Health Sciences, Hong Kong, P.R. China. 3. Faculty of Medicine, Newcastle University, Newcastle Upon Tyne. 4. Department of Pharmacy & Pharmacology, University of Bath, Bath, UK. 5. Department of Microbiology. 6. Department of Anaesthesia and Intensive Care, Faculty of Medicine, Chinese University of Hong Kong. 7. Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong. 8. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin. 9. Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong. 10. Department of Medicine and Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong. 11. Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, P.R. China.
Abstract
OBJECTIVES: The aim of this study is to determine major adverse cardiovascular events (MACE) and all-cause mortality comparing between xanthine oxidase inhibitors (XOIs) and non-XOI users, and between allopurinol and febuxostat. METHODS: This is a retrospective cohort study of gout patients prescribed anti-hyperuricemic medications between 2013 and 2017 using a territory-wide administrative database. XOI users were matched 1:1 to XOI non-users using propensity scores. Febuxostat users were matched 1:3 to allopurinol users. Subgroup analyses were conducted based on colchicine use. RESULTS: Of the 13 997 eligible participants, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users. After propensity score matching, compared with non-users (n = 3607), XOI users (n = 3607) showed similar incidence of MACE (hazard ratio [HR]: 0.997, 95% CI, 0.879, 1.131; P>0.05) and all-cause mortality (HR = 0.972, 95% CI 0.886, 1.065, P=0.539). Febuxostat (n = 276) users showed a similar risk of MACE compared with allopurinol users (n = 828; HR: 0.672, 95% CI, 0.416, 1.085; P=0.104) with a tendency towards a lower risk of heart failure-related hospitalizations (HR = 0.529, 95% CI 0.272, 1.029; P=0.061). Concurrent colchicine use reduced the risk for all-cause mortality amongst XOI users (HR = 0.671, 95% 0.586, 0.768; P<0.001). CONCLUSION: In gout patients, XOI users showed similar risk of MACE and all-cause mortality compared with non-users. Compared with allopurinol users, febuxostat users showed similar MACE and all-cause mortality risks but lower heart failure-related hospitalizations.
OBJECTIVES: The aim of this study is to determine major adverse cardiovascular events (MACE) and all-cause mortality comparing between xanthine oxidase inhibitors (XOIs) and non-XOI users, and between allopurinol and febuxostat. METHODS: This is a retrospective cohort study of goutpatients prescribed anti-hyperuricemic medications between 2013 and 2017 using a territory-wide administrative database. XOI users were matched 1:1 to XOI non-users using propensity scores. Febuxostat users were matched 1:3 to allopurinol users. Subgroup analyses were conducted based on colchicine use. RESULTS: Of the 13 997 eligible participants, 3607 (25.8%) were XOI users and 10 390 (74.2%) were XOI non-users. After propensity score matching, compared with non-users (n = 3607), XOI users (n = 3607) showed similar incidence of MACE (hazard ratio [HR]: 0.997, 95% CI, 0.879, 1.131; P>0.05) and all-cause mortality (HR = 0.972, 95% CI 0.886, 1.065, P=0.539). Febuxostat (n = 276) users showed a similar risk of MACE compared with allopurinol users (n = 828; HR: 0.672, 95% CI, 0.416, 1.085; P=0.104) with a tendency towards a lower risk of heart failure-related hospitalizations (HR = 0.529, 95% CI 0.272, 1.029; P=0.061). Concurrent colchicine use reduced the risk for all-cause mortality amongst XOI users (HR = 0.671, 95% 0.586, 0.768; P<0.001). CONCLUSION: In goutpatients, XOI users showed similar risk of MACE and all-cause mortality compared with non-users. Compared with allopurinol users, febuxostat users showed similar MACE and all-cause mortality risks but lower heart failure-related hospitalizations.
Authors: Jiandong Zhou; Sharen Lee; Wing Tak Wong; Khalid Bin Waleed; Keith Sai Kit Leung; Teddy Tai Loy Lee; Abraham Ka Chung Wai; Tong Liu; Carlin Chang; Bernard Man Yung Cheung; Qingpeng Zhang; Gary Tse Journal: J Am Med Inform Assoc Date: 2022-01-12 Impact factor: 7.942
Authors: Jiandong Zhou; Sharen Lee; Xiansong Wang; Yi Li; William Ka Kei Wu; Tong Liu; Zhidong Cao; Daniel Dajun Zeng; Keith Sai Kit Leung; Abraham Ka Chung Wai; Ian Chi Kei Wong; Bernard Man Yung Cheung; Qingpeng Zhang; Gary Tse Journal: NPJ Digit Med Date: 2021-04-08
Authors: Sharen Lee; Jiandong Zhou; Keith Sai Kit Leung; William Ka Kei Wu; Wing Tak Wong; Tong Liu; Ian Chi Kei Wong; Kamalan Jeevaratnam; Qingpeng Zhang; Gary Tse Journal: BMJ Open Diabetes Res Care Date: 2021-06